AgomAb Therapeutics NV ( AGMB) has filed to raise $200 million in development capital in an IPO of its American Depositary Shares representing underlying common shares, according to SEC F-1/A ...
New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果